cVLP Nipah Virus Vaccine
Nipah Virus Infection
Pre-clinicalActive
Key Facts
About AdaptVac
AdaptVac is a clinical-stage vaccine developer with a validated, proprietary cVLP display platform. The company has advanced its platform through a Phase 3 COVID-19 vaccine (ABNCoV2) and has a pipeline including a HER2+ breast cancer vaccine in Phase 1 and a Nipah virus vaccine in pre-clinical development. With strong academic roots from the University of Copenhagen and significant non-dilutive funding, AdaptVac is positioned to create durable vaccines for both commercial and equitable access markets. Its business model is primarily out-licensing of vaccine candidates developed on its platform.
View full company profileTherapeutic Areas
Other Nipah Virus Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| Nipah Virus Vaccine | Phylex BioSciences | Pre-clinical |
| NIPAH Program | Fabentech | Proof of Concept |